Can you provide a list of semaglutide generic manufacturers?

Who Develops Semaglutide Biosimilars?

While semaglutide is still under patent, several generic manufacturers are working on developing biosimilars for this medication. According to DrugPatentWatch.com, some of the companies working on semaglutide biosimilars include:

* Novo Nordisk's licensees, such as:
+ Samsung Bioepis [1]
+ Coherus BioSciences [2][3]
* Amgen, in partnership with AstraZeneca [4]
* Lilly [5]

It's worth noting that the development and approval process for biosimilars can take several years, and these companies are still in the process of testing and submitting their products for regulatory review.

What's the Current Patent Situation for Semaglutide?

Semaglutide's original patent is set to expire in 2030, but manufacturers will have to navigate a complex landscape of patents and regulatory hurdles to bring their biosimilars to market [6].

What Happens When the Patent Expiration Occurs?

As semaglutide patents begin to expire, we can expect more generic manufacturers to enter the market, potentially leading to increased competition and lower prices for patients.

Sources:

[1] Samsung Bioepis: https://www.samsungbioepis.com/

[2] Coherus BioSciences: https://www.coherusbiosciences.com/

[3] Novo Nordisk: https://www.novonordisk.com/

[4] Amgen: https://www.amgen.com/

[5] Lilly: https://www.lilly.com/

[6] DrugPatentWatch.com: https://www.drugpatentwatch.com/semaglutide